Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01501487 · ClinicalTrials.gov registry record · Phase 4
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
A Phase 4 study, sponsored by Agendia.
- Completed
- Registry status
- Phase 4
- Development phase
- 226
- Enrollment target
NCT01501487 is a Phase 4 study that has completed, run by Agendia. The registered enrollment target is 226 participants.
The verdict
NCT01501487, a Phase 4 study, has completed, sponsored by Agendia.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 226 participants
- Enrollment target
Study Summary
Genomics assays that measure specific gene expression patterns in a patient's primary tumor have become important prognostic tools for breast cancer patients. This study is designed to test the ability of MammaPrint® in combination with TargetPrint®, BluePrint®, and TheraPrint®, as well as traditional pathologic and clinical prognostic factors, to predict responsiveness to neo-adjuvant chemotherapy in patients with locally advanced breast cancer (LABC).
Interventions
- DRUG TAC chemotherapy
- DRUG TC chemotherapy
- DRUG Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy
- DRUG TCH chemotherapy
- DRUG T + trastuzumab followed by CEF + trastuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2011-10 |
| Est. Completion | 2017-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01501487
The ClinicalTrials.gov registry entry for NCT01501487 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agendia, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which TAC chemotherapy is the first listed.
NCT01501487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01501487 about?
NCT01501487 is a clinical study titled "MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I". Genomics assays that measure specific gene expression patterns in a patient's primary tumor have become important prognostic tools for breast cancer patients. This study is designed to test the ability of MammaPrint® in combination with TargetPrint®, BluePrint®, and TheraPrint®, as well as tradition...
What is the current status of trial NCT01501487?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 226 participants. The study started on 2011-10. Estimated completion is 2017-06.
What interventions are being tested in trial NCT01501487?
The interventions under investigation include: TAC chemotherapy (DRUG), TC chemotherapy (DRUG), Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy (DRUG), TCH chemotherapy (DRUG), T + trastuzumab followed by CEF + trastuzumab (DRUG).
Who is sponsoring clinical trial NCT01501487?
This trial is sponsored by Agendia, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.